| NCT ID | NCT03327779 |
| Status | Recruiting |
| Phase | — |
| Sponsor | World Federation of Hemophilia |
| Condition | Hemophilia A |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2018-01-26 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 2018-01-26 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The WBDR is an international observational disease registry of patients with hemophilia. It will provide a platform for a network of hemophilia treatment centres (HTCs) around the world to collect uniform and standardized patient data and guide clinical practice. With informed consent from the patient, the WBDR stores anonymous data about the person's disease, such as hemophilia type and severity, symptoms, and treatment.
Eligibility Criteria
Inclusion Criteria: * Patients of participating Hemophilia Treatment Centres with Hemophilia A or B, or von Willebrand Disease Exclusion Criteria: * none
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03327779 clinical trial?
This trial is open to participants of all sexes, studying Hemophilia A. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03327779 currently recruiting?
Yes, NCT03327779 is actively recruiting participants. Contact the research team at dcoffin@wfh.org for enrollment information.
Where is the NCT03327779 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT03327779 clinical trial?
NCT03327779 is sponsored by World Federation of Hemophilia. The trial plans to enroll 20,000 participants.